# ADG126

Source: https://onco.cc/drugs/adg126/  
OnCo record `adg126` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ADG126 is an experimental monoclonal antibody from Adagene in phase 2 trials for hepatocellular carcinoma, aimed at CTLA-4.

## Summary

ADG126 is a monoclonal antibody developed by Adagene and Sanofi. Its target is CTLA-4 (the sponsor names CTLA-4). The sponsor states: A fully human anti-CTLA-4 monoclonal antibody that specifically binds to human CTLA-4. ClinicalTrials.gov describes the intervention as: ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in hepatocellular carcinoma. The largest, NCT05584670, plans to enrol 542 participants with primary completion expected 2027-01-19. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: A fully human anti-CTLA-4 monoclonal antibody that specifically binds to human CTLA-4.

## Sources

- ClinicalTrials.gov: trials of ADG126: https://clinicaltrials.gov/search?intr=ADG126

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/), [Sanofi](https://onco.cc/companies/sanofi/)
- trials: [A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05584670/), [A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li](https://onco.cc/trials/nct04524871/), [ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05405595/), [Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct06846268/)

---
JSON: https://onco.cc/api/v1/entities/adg126.json